ROME, ITALY — Using the factor Xa inhibitor edoxaban (Savaysa/Lixiana, Daiichi Sankyo) to anticoagulate patients about to undergo electrical cardioversion for their atrial fibrillation (AF) seems ...

A Food and Drug Administration (FDA) advisory committee has voted 11 to 2 against a recommendation that the agency approve a long-studied antiarrhythmic agent for cardioversion of recent-onset atrial ...

A team of Ochsner Health cardiologists recently published an article in the Journal of the American Medical Association (JAMA) Cardiology comparing two treatment strategies for patients with atrial ...

Atrial fibrillation, also called AFib, is a complex condition with many causes. Blood pressure problems are just one of the risk factors. But atrial fibrillation itself can lead to changes in blood ...

Bayer AG BAYRY announced that it has initiated a phase I study, which is evaluating its investigational highly selective GIRK4 inhibitor, BAY 3670549, for the treatment of patients with atrial ...